Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

52 public trials 12 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

NCT05804032

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Universitätsklinikum Krems Krems, Austria
  • Ordensklinikum Linz Linz, Austria
  • Landeskrankenhaus Feldkirch-Rankweil Rankweil, Austria
  • Universitätsklinikum der Paracelsus, 3. Med. Abteilung/Onkologie Ambulanz Salzburg, Austria
View all 91 locations
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details
Completed

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

NCT01183949

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Centre New York, United States
View Trial Details
Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

NCT01063907

Conditions
Blood Protein Disorders, Bronchial Diseases, Bronchiolitis, +28 more
Locations
  • Arizona Clinical Research Center, Inc. / Arizona Oncology Associates, 1825 N Kolb, Tucson, Arizona, United States
  • Pacific Shores Medical Group 1043 Elm Ave, Suite 104 Long Beach, California, United States
  • UCLA Medical Center Hematology / Oncology Division, 10945 Le Conte Ave #2333, Los Angeles, California, United States
  • Collaborative Research Group 2320 S Seacrest Blvd, Suite 202 Boynton Beach, Florida, United States
View all 26 locations
View Trial Details
Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019

Conditions
Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, +34 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Fayetteville, Arkansas, United States
  • Research Site Anaheim, California, United States
  • Research Site Campbell, California, United States
View all 309 locations
View Trial Details
Completed

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

NCT00821249

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Emory University, Winship Cancer Institute Atlanta, Georgia, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
  • MD Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions